NCT01836120

A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Hebei Tumor Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

A study of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with Gastric Cancer.The purpose of this study is to compare the activity of Raltitrexed plus Docetaxel versus Docetaxel as second-line chemotherapy in subjects with gastric carcinoma by estimating progression free survival (PFS) in each treatment arm.

Conditions

• Gastric Cancer

Interventions

Type	Name	Description
DRUG	Raltitrexed plus Docetaxel	Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d 1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)
DRUG	Docetaxel	Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)

Timeline

• Start date: 2013-04-01
• Primary completion: 2016-12-01
• Completion: 2017-06-01
• First posted: 2013-04-19
• Last updated: 2013-04-19

Locations

1 site across 1 country: China